Unicycive rises on narrower quarterly loss
UNCY•UNCY•UNCY•UNCY•Shares of drug developer Unicycive Therapeutics UNCY.O rise 9.2% to $5.46
Co posted Q2 net loss of $1.7 million, compared to a net loss of $6.5 million a year ago
Co says the decreased net loss was attributed primarily to a decrease in the fair value of the co's warrant liability
UNCY plans to resubmit marketing application for oxylanthanum carbonate after FDA facility inspection
In June, U.S. FDA had declined to approve oxylanthanum carbonate to treat elevated phosphate levels in patients on dialysis due to chronic kidney diseases
Including session's move, stock down 5.9% YTD
